A Phase IA/IB, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase IA/IB, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs BGB 290 (Primary)
  • Indications Breast cancer; Cancer; Glioblastoma; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 12 Sep 2017 Results of phase 1a (As of 1 May 2017; n=45) presented at the 42nd European Society for Medical Oncology Congress
    • 08 Sep 2017 Results presented in a BeiGene media release.
    • 08 Sep 2017 According to a BeiGene media release, as of June 1, 2017, 68 patients have been enrolled in this trial, with 45 patients in the Phase 1 component, and 23 patients in the Phase 2 component. Jason Lickliter is the coordinating principal investigator of the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top